FY2030 Earnings Estimate for PVLA Issued By HC Wainwright

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – HC Wainwright issued their FY2030 EPS estimates for shares of Palvella Therapeutics in a report released on Monday, February 9th. HC Wainwright analyst A. Fein forecasts that the company will earn $7.05 per share for the year. HC Wainwright currently has a “Buy” rating and a $200.00 price objective on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Monday, November 10th. The company reported ($1.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.18).

Several other brokerages have also recently weighed in on PVLA. TD Cowen restated a “buy” rating on shares of Palvella Therapeutics in a research report on Monday, February 2nd. Truist Financial lifted their price target on Palvella Therapeutics from $105.00 to $190.00 and gave the stock a “buy” rating in a research report on Monday, December 15th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $193.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. BTIG Research restated a “buy” rating and set a $192.00 price target on shares of Palvella Therapeutics in a report on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Palvella Therapeutics in a research note on Monday, December 29th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $158.69.

Palvella Therapeutics Price Performance

NASDAQ:PVLA opened at $77.88 on Tuesday. The company has a market cap of $922.10 million, a price-to-earnings ratio of -29.61 and a beta of -0.16. Palvella Therapeutics has a 1 year low of $14.68 and a 1 year high of $114.69. The stock’s 50 day simple moving average is $94.35 and its two-hundred day simple moving average is $74.85.

Institutional Trading of Palvella Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. First Light Asset Management LLC bought a new position in Palvella Therapeutics in the third quarter worth approximately $33,949,000. Federated Hermes Inc. bought a new position in shares of Palvella Therapeutics during the 3rd quarter worth $21,255,000. Vanguard Group Inc. increased its stake in shares of Palvella Therapeutics by 202.0% during the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock valued at $31,010,000 after buying an additional 330,847 shares during the period. Jennison Associates LLC increased its stake in shares of Palvella Therapeutics by 262.4% during the fourth quarter. Jennison Associates LLC now owns 387,483 shares of the company’s stock valued at $40,558,000 after buying an additional 280,573 shares during the period. Finally, Millennium Management LLC bought a new stake in shares of Palvella Therapeutics in the first quarter valued at about $7,553,000. Institutional investors own 40.11% of the company’s stock.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last quarter, insiders have sold 12,906 shares of company stock valued at $1,205,980. Company insiders own 20.50% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.